Poor Science; Poorly Trained Scientists; Poor Policies: Major Deterrents to the War on Cancer
- Authors
-
-
Leslie C. Costello
School of Dentistry Department of Oncology and Diagnostic Sciences and the Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland 21201, USA
-
- Keywords:
- Cancer, NIH policies, training of scientists, excessive molecular biology, holistic physiological/pathophysiological approach.
- Abstract
-
Although the availability of funding has been described as the major limitation on advances in cancer, the progress in the war on cancer has been deterred mainly by poor science, poorly trained scientists, and poor NIH policies. This is the result of NIH policies of its extreme focus on molecular biology (genomics, molecular genetics, molecular biology) identification of the molecular factors and pathways; which are required for the acceptability of treatment and preventive protocols. As such, this has influenced virtually all agencies that provide grants for medical research to adopt the NIH policies. This has impacted the funding of the research as well as the focus of the training of scientists. Directors of NCI Dr. Varmus (also Nobel Prize awardee) and Dr. Zerhouni had addressed this issue; and they rejected the necessity of molecular biology studies and information. NIH should return to the holistic physiological/pathophysiological approach to studies of cancer issues. This would provide the best approach for winning the war on cancer.
- Downloads
-
Download data is not yet available.
- References
-
Zerhouni E. The NIH roadmap. Science 2003; 332: 63-5. https://doi.org/10.1126/science.1091867
Leaf C. Why we're losing the war on cancer (and how to win it). Fortune 2004; 149(6): 76-82.
Costello LC. The effect of contemporary education and training of biomedical scientists on present and future medical research. Acad Med 2009; 84: 459-63. https://doi.org/10.1097/ACM.0b013e31819a7c6b
Perspective: Is NIH funding the "best science by the best scientists"? A critique of the NIH R01 research grant review policies. Acad Med 2010; 85(5): 775-9. https://doi.org/10.1097/ACM.0b013e3181d74256
National Institutes of Health. Enhancing Peer Review at NIH: Overview. Available at: http://enhancing-peer-review.nih.gov/index.html. Accessed January 18, 2010
Office of Extramural Research, National Institutes of Health. Encouraging Early Transition to Research Independence: Modifying the NIH New Investigator Policy to Identify Early Stage Investigators. Available at: http://grants.nih.gov/grants/guide/notice-files/NOT-OD-08-121.html. Accessed January 18, 2010.
Bernard C. An Introduction to the Study of Experimental Medicine. New York, NY: The Macmillan Company 1927.
- Downloads
- Published
- 15-08-2018
- Issue
- Vol. 7 No. 3 (2018)
- Section
- Articles
How to Cite
Similar Articles
- Lisa Billecke, Eva Maria Murga Penas, Jozef Zustin, Thorsten Derlin, Carsten Bokemeyer, Georgia Schilling, Extramedullary Plasmacytoma of the Lung - Rather a Disseminated than a Localized Disease? - A Case Report of a Primary Pulmonary Plasmacytoma Showing Distinct Signs of Systemic Spread , Journal of Cancer Research Updates: Vol. 1 No. 1 (2012)
- Tao Xu, Weihong Wei, Zeli Huang, Weihan Hu, Case Report: Coexistence of Non-Keratinizing Squamous Cell Carcinoma and Follicular Lymphoma in Nasopharynx , Journal of Cancer Research Updates: Vol. 3 No. 2 (2014)
- Shorouk G. Badr, Hesham Tawfik, Mohammad Hamdy Abo-Ryia, Ayman Mohamed El Saqa, Fatma Gharib, Total Neoadjuvant Therapy Versus Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer, Who will Gain Maximum Benefit? A Prospective Randomized Study , Journal of Cancer Research Updates: Vol. 15 No. 3 (2026)
- J.L. Layton, J.F. Renzulli II, A.M. Taber, D. Golijanin, J.E. Collins, H.H. Safran, A.E. Mega, Weekly Neoadjuvant Ixabepilone on Surgical Feasibility and Clinical Outcomes in Locally Advanced High-Risk Prostate Cancer: A Phase II Clinical Trial , Journal of Cancer Research Updates: Vol. 2 No. 4 (2013)
- Yi Zheng, Ji-Ye Yin, Ying Wang, Xiang-Ping Li, Juan Chen, Chen-Yue Qian, Xiao-Ke Wen, Wei Zhang, Hong-Hao Zhou, Zhao-Qian Liu, The Association of Genetic Polymorphisms of TNFα, TNF-R1, and TNF-R2 and Lung Cancer Chemotherapy Response , Journal of Cancer Research Updates: Vol. 3 No. 4 (2014)
- Carolina Bellera, Melisa E. Gantner, María E. Ruiz, Alan Talevi, Recent Advances on Nanotechnology Applications to Cancer Drug Therapy , Journal of Cancer Research Updates: Vol. 2 No. 3 (2013)
- Runjun Shi, Jie Chen, Jinchang Wu, Jundong Zhou, PET/CT and MRI in Evaluating Cervical Cancer , Journal of Cancer Research Updates: Vol. 5 No. 1 (2016)
- Yuling Chen, Sui-Lin Mo, Felix Wu Shun Wong, George Qian Li, Yen Siew Loh, Basil D. Roufogalis, Maureen V. Boost, Daniel Man-Yuen Sze, Factors Influencing Percentage Yield of Side Population Isolated in Ovarian Cancer Cell LineSK-OV-3 , Journal of Cancer Research Updates: Vol. 3 No. 1 (2014)
- Zahraa A.G. AL Ghuraibawi, Mohammed Mahmood Kamil, Khaleel Ibraheem Mohson, Zainab Ghazi Sadeq, Mareym M. Alkhaiat, Hematological Parameters in Liver Metastasis: A Comprehensive Clinical Evaluation for Early Detection in Iraqi Patients , Journal of Cancer Research Updates: Vol. 14 (2025)
- M.M. Soldevilla, A. Lopez-Diaz de Cerio, S. Inoges, F. Pastor, H. Villanueva, M. Bendandi, Anti-Idiotype Antibodies in Cancer Treatment , Journal of Cancer Research Updates: Vol. 1 No. 2 (2012)
You may also start an advanced similarity search for this article.